{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00374855: Phase 2 Interventional Completed Mild Hypertension
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03796637: Phase 2 Interventional Completed Duchenne Muscular Dystrophy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04406727: Phase 3 Interventional Not yet recruiting HIV-1 Infection
(2023)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01832051: Phase 2 Interventional Completed Metastatic Breast Cancer
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03514121: Early Phase 1 Interventional Terminated Breast Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00345618: Phase 3 Interventional Completed Embolism
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01009424: Phase 1 Interventional Withdrawn COPD
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03573934: Not Applicable Interventional Completed Healthy
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:luveltamab tazide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04129164: Phase 2 Interventional Completed Sjögren's Syndrome
(2019)
Source URL:
Class:
PROTEIN
